Article Information
- Received August 8, 2013
- Revision received February 9, 2014
- Accepted March 11, 2014
- First published May 21, 2014.
- Version of record published May 21, 2014.
Author contributions
Author contributions: Q.-L.M., S.A.F., and G.M.C. designed research; Q.-L.M., X.Z., F.Y., O.J.U., D.J.G., M.A., N.C.K., S.N., P.P.C., S.A.F., and G.M.C. performed research; F.N. and P.C. contributed unpublished reagents/analytic tools; Q.-L.M., D.J.G., N.C.K., E.T. and S.A.F. analyzed data; Q.-L.M., S.A.F., and G.M.C. wrote the paper.
↵*S.A.F. and G.M.C. contributed equally to this work.
Disclosures
- Received August 8, 2013.
- Revision received February 9, 2014.
- Accepted March 11, 2014.
This work was supported by the National Institutes of Health (Grant AT003008 to G.M.C.; Grant P01AG16570 from the Alzheimer's Disease Research Center to G.M.C.; Grant RC1AG035878 to G.M.C. and S.A.F.; Grant AG13471 to G.M.C.; Grant U01 28583 to S.A.F.; and Grant R01AG021975 to S.A.F.), the Alzheimer's Association (Grant NIRG-07-59659 to Q.L.M.), the UCLA Alzheimer's Disease Research Center Mary S. Easton Drug Discovery Program (G.M.C.), the UCLA Mary S. Easton Translational Center (G.M.C., S.A.F.), and David and Dr. Sharon Comden (S.A.F., G.M.C.). X.Z. was supported by the Beijing High Standard Health Human Resource Cultural Program (Grant e1e12 to P.P.C.). The polyclonal antibody to dephosphorylated, active MAP2 “MAP2 972” was provided by Jesus Avíla, PhD (Professor, Universidad Autónoma de Madrid, Spain).
The authors declare no competing financial interests.
- Correspondence should be addressed to either Greg. M. Cole or Sally A. Frautschy, Mary S. Easton Translational Center, Veterans Greater Los Angeles Healthcare, 11301 Wilshire Blvd., Bldg. 113, Rm. 312, Los Angeles, CA 90073. gmcole{at}ucla.edu or frautsch{at}ucla.edu
Online Impact